natgillin/translations-raw huggingface dataset:
QUANTITY OF THE ACTIVE SUBSTANCE(S) CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ODMERKOV
STATEMENT OF ACTIVE SUBSTANCES Hydrocortisone aceponate 1.11 mg/ml, Miconazole as nitrate 15.1 mg/ml, Gentamicin as sulphate 1,505 IU/ml. 
NAVEDBA UČINKOVIN Hidrokortizon aceponat 1.11 mg/ml, Mikonazol v obliki nitrata 15.1 mg/ml, Gentamicin v obliki sulfata 1,505 IU/ml.
NAME OF THE VETERINARY MEDICINAL PRODUCT Easotic ear drops, suspension for dogs 
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI Easotic kapljice za uho, suspenzija za pse
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) 
Pogostost neželenih učinkov je določena po naslednjem dogovoru: - zelo pogosti (neželeni učinki se pokažejo pri več kot 1 od 10 zdravljenih živali) - pogosti (pri več kot 1, toda manj kot 10 živali od 100 zdravljenih živali)
Introduce the atraumatic canula in the ear canal. 
Uvedite atravmatsko kanilo v ušesni kanal.
• Introduce the atraumatic cannula in the ear canal. 
• Uvedite atravmatsko kanilo v ušesni kanal.
1,505 IU/ml. 
1505 i.e./ml.
Shake the pipette thoroughly before use. 
Pred uporabo jo dobro pretresite.
EXPIRY DATE EXP {month/year} Once opened use within 10 days. 
Odprto zdravilo porabite v 10 dneh.
EU/2/08/085/001-006 
ŠTEVILKA DOVOLJENJA ZA PROMET EU/2/08/085/001/006
MATERIALS, IF ANY 
UPORABE, če je navedba smiselna
Easotic ear drops, suspension for dogs 
NAVODILO ZA UPORABO Easotic kapljice za uho suspenzija za pse
PACKAGE SIZE 10 ml (10 doses). 
FARMACEVTSKA OBLIKA Kapljice za uho, suspenzija VELIKOST PAKIRANJA 10 ml (10 odmerkov).
Shake the bottle thoroughly before first administration and prime the pump by pressing it. Introduce the atraumatic canula in the ear canal. 
Pred prvo uporabo dobro pretresite stekleničko in s pritiskom napolnite črpalko.
76505 Saue/Harjumaa, ESTONIA 
ET - 76505 Saue/Harjumaa, ESTONIA Tel: + 372 6 709 006
STATEMENT OF THE MRLs 
NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVIA (MRL)
WITHDRAWAL PERIOD(S) SPECIAL WARNING(S), IF NECESSARY Read the package leaflet before use. 
ZDRAVILA ALI ODPADNIH SNOVI, ČE OBSTAJAJO Odstranjevanje: preberite navodilo za uporabo.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PIPETTE NAME OF THE VETERINARY MEDICINAL PRODUCT Easotic 
PODATKI, KI MORAJO BITI NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH KAPALKA
Slovenija VIRBAC 1ère avenue 2065 m - L.I.D 06516 Carros FRANCE 
Hrvaška VIRBAC 1ère avenue 2065 m - L.I.D 06516 Carros FRANCE
Pre-filled syringe (glass) with needle guard 
napolnjena injekcijska brizga (steklo) z varovalom za iglo
2 pre-filled pens + 2 alcohol wipes 
2 odmerna vložka + 2 alkoholna zloženca
London, 24 January 2008 Doc. 
London, 24. januar 2008 Sklic na dok.
The company that applied for authorisation is Wyeth Europa Ltd. 
Družba, ki je podala vlogo za odobritev dovoljenja za promet, je Wyeth Europa Ltd.
Ref. EMEA/37537/2008 
EMEA/186664/2008
International non-proprietary name (INN): gemtuzumab ozogamicin 
Mednarodno nelastniško ime (INN): gemtuzumab ozogamicin
After having considered the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the refusal of the marketing authorisation on 24 January 2008. 
Po preučitvi podlage za to zahtevo je CHMP ponovno pregledal prvotno mnenje in dne 24. januarja 2008 potrdil zavrnitev vloge za dovoljenje za promet.
In all three studies, the main measure of effectiveness was the proportion of patients who achieved ‘complete remission' after a seven-month course of treatment. 
V vseh treh študijah je bil glavno merilo učinkovitosti delež bolnikov, ki so po sedemmesečnem zdravljenju dosegli „popolno remisijo“ .
QUESTIONS AND ANSWERS ON RECOMMENDATION FOR THE REFUSAL OF THE MARKETING AUTHORISATION for MYLOTARG 
VPRAŠANJA IN ODGOVORI GLEDE PRIPOROČILA ZA ZAVRNITEV VLOGE ZA DOVOLJENJE ZA PROMET z zdravilom MYLOTARG
These included severe and long-lasting bone marrow suppression causing low levels of white blood cells and platelets, liver problems, and side effects related to the infusion, such as chills, fever and low blood pressure. 
Le-ti so vključevali resno in dolgotrajno supresijo kostnega mozga, ki povzroča nizko raven belih krvničk in ploščic, težave z jetri ter stranske učinke, povezane z infundiranjem, kot npr. mrzlico, povišano telesno temperaturo in nizek krvni tlak.
A small proportion of the patients whose disease had come back after one previous course of treatment achieved complete remission. 
Majhen delež bolnikov, pri katerih se je bolezen ponovno pojavila po enem predhodnem zdravljenju, je dosegel popolno remisijo.
However, it was difficult to compare the effectiveness of Mylotarg and other treatments used for this disease, in terms of how long remission would last, how long it would take until the disease got worse, or what the medicines' effects would be on survival. 
Vendar pa je bilo težko primerjati učinkovitost zdravila Mylotarg in drugih zdravil za to bolezen z vidika trajanja remisije, dolžine obdobja do poslabšanja ali učinkov zdravila na preživetje.
The effects of Mylotarg were first tested in experimental models before being studied in humans. 
Učinki zdravila Mylotarg so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
What are the consequences of the refusal for patients in clinical trials or compassionate use programmes using Mylotarg? 
Kakšne so posledice zavrnitve za bolnike, ki sodelujejo v kliničnih preskušanjih ali programih sočutne uporabe zdravila Mylotarg?
It was to be used in patients who were ‘CD33-positive', meaning that their cancerous white blood cells had a protein called CD33 on their surface. 
Uporabljalo naj bi se pri bolnikih, ki so „pozitivni na CD33“, kar pomeni, da imajo njihove rakave bele krvničke na površini beljakovino, imenovano CD33.
The company also stated that it will continue to supply Mylotarg for use in existing, ongoing clinical trials. 
Družba je prav tako izjavila, da bo nadaljevala z dobavo zdravila Mylotarg, namenjenega za uporabo v kliničnih preskušanjih, ki so v teku.
Mylotarg was not compared to any other treatment in any of the studies. 
Zdravila Mylotarg v nobeni študiji niso primerjali s kakim drugim zdravljenjem.
The company informed the CHMP that patients currently included in compassionate use programmes will continue to receive Mylotarg until they have finished their course of treatment. 
Družba je CHMP obvestila, da bodo bolniki, ki so trenutno vključeni v programe sočutne uporabe, prejemali zdravilo Mylotarg, dokler ne zaključijo zdravljenja.
When the antibody attaches to CD33, the cells absorb the antibody, as well as the cytotoxic substance that it is attached to. 
Ko se protitelo veže na CD33, celice absorbirajo protitelo, prav tako pa tudi citotoksično učinkovino, ki je vezana nanj.
The effects of Mylotarg were studied in three main studies involving a total of 277 patients with CD33-positive acute myeloid leukaemia, whose disease had come back after one previous course of treatment. 
Zdravilo Mylotarg so preučevali v treh glavnih študijah s skupno 277 bolniki z akutno mieloično levkemijo, pozitivno na CD33, pri katerih se je bolezen ponovila po enem predhodnem zdravljenju.
At that point in time, the CHMP was of the opinion that there was insufficient evidence to establish the effectiveness of Mylotarg in the treatment of acute myeloid leukaemia, and therefore that the medicine's benefits did not outweigh its risks. 
Takrat je bil CHMP mnenja, da ni zadostnih dokazov, da bi lahko določili učinkovitost zdravila Mylotarg pri zdravljenju akutne mieloične levkemije, zato koristi zdravila ne odtehtajo z njim povezanih tveganj.
The Committee noted that there were side effects associated with Mylotarg. 
Odbor je ugotovil, da so z zdravilom Mylotarg povezani stranski učinki.
The calicheamicin then breaks up the leukaemia cells' DNA, eventually killing the cells. 
Kaliheamicin razbije DNK celic levkemije ter tako postopoma ubije celice.
On 20 September 2007, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Mylotarg 5 mg powder for solution for infusion, intended for the treatment of acute myeloid leukaemia. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je v svojem negativnem mnenju z dne 20. septembra 2007 priporočil zavrnitev vloge za dovoljenje za promet z zdravilom Mylotarg, 5 mg praškom za pripravo raztopine za infundiranje, namenjenim za zdravljenje akutne mieloične levkemije.
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found on certain cells in the body. 
Monoklonsko protitelo je protitelo (tip beljakovine), ki je bilo oblikovano tako, da prepozna in se veže na specifično strukturo (imenovano antigen), ki se nahaja na posameznih celicah v telesu.
Mylotarg was to be used to treat patients whose disease had come back after one previous course of treatment, and who were not suitable for other types of intensive chemotherapy such as highdose cytarabine (another anticancer medicine). 
Zdravilo Mylotarg bi naj bilo namenjeno zdravljenju bolnikov, katerih bolezen se je ponovno pojavila po predhodnem zdravljenju, in ki niso bili primerni za druge vrste intenzivne kemoterapije, npr. s citarabinom (drugim zdravilom proti raku) v visokem odmerku.
Mylotarg was expected to be used to treat acute myeloid leukaemia, a type of cancer of the white blood cells. 
Zdravilo Mylotarg bi se naj uporabljalo za zdravljenje akutne mieloične levkemije, vrste raka belih krvničk.
What is Mylotarg? 
Kaj je zdravilo Mylotarg?
The CHMP refusal was confirmed after re-examination. 
Po ponovni presoji je bila zavrnitev s strani CHMP potrjena.
It contains the active substance gemtuzumab ozogamicin. 
Vsebuje zdravilno učinkovino gemtuzumab ozogamicin.
Mylotarg was designated as an orphan medicinal product on 18 October 2000 for acute myeloid leukaemia. 
Zdravilo Mylotarg je bilo 18. oktobra 2000 določeno kot zdravilo sirota za zdravljenje akutne mieloične levkemije.
The CHMP was concerned that the studies of Mylotarg had not shown a benefit of the medicine, because of the way they were designed. 
CHMP je izrazil skrb, da študije z zdravilom Mylotarg zaradi svoje zasnove niso izkazale koristi zdravila.
Inside the cells, the cytotoxic substance, which is called calicheamicin, is released. 
Znotraj celice se citotoksična učinkovina, imenovana kaliheamicin, sprosti.
What was Mylotarg expected to be used for? 
Za kaj naj bi se zdravilo Mylotarg uporabljalo?
Hence, the CHMP recommended that Mylotarg be refused marketing authorisation. 
Iz tega razloga je CHMP priporočil zavrnitev dovoljenja za promet z zdravilom Mylotarg.
Mylotarg is a powder that is made up into a solution for infusion (drip into a vein). 
Zdravilo Mylotarg je prašek za pripravo raztopine za infundiranje (dajanje v veno).
How is Mylotarg expected to work? 
Kako naj bi zdravilo Mylotarg delovalo?
The active substance in Mylotarg, gemtuzumab ozogamicin, is a cytotoxic (cell-killing) substance that is linked to a monoclonal antibody. 
Gemtuzumab ozogamicin, zdravilna učinkovina v zdravilu Mylotarg, je citotoksična učinkovina (učinkovina, ki ubija celice), ki je vezana na monoklonsko protitelo.
Complete remission is when the leukaemia cells can no longer be detected in the blood and are at very low levels in the bone marrow. 
O popolni remisiji govorimo, ko v krvi celic levkemije ni več
The monoclonal antibody part of the active substance (gemtuzumab) has been designed to bind to CD33, an antigen which is found on the surface of acute myeloid leukaemia cells in about 80% of patients. 
antigen, ki ga pri približno 80 % bolnikov najdemo na površini celic akutne mieloične levkemije.
The study was then extended to four years. 
Študija je bila nato podaljšana na štiri leta.
All patients should be assessed at least once every two years. 
Vse bolnike je treba oceniti vsaj enkrat na dve leti.
Further information on Rebif can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/rebif. 
Nadaljnje informacije za zdravilo Rebif so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/rebif.
Other information about Rebif 
Druge informacije o zdravilu Rebif
What measures are being taken to ensure the safe and effective use of Rebif? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Rebif?
The European Medicines Agency decided that Rebif's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Rebif večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
The patients had experienced at least two relapses in the previous two years. 
Bolniki so imeli vsaj dva zagona v preteklih dveh letih.
Rebif received a marketing authorisation valid throughout the EU on 4 May 1998. 
Za zdravilo Rebif je bilo 4. maja 1998 izdano dovoljenje za promet, veljavno po vsej EU.
As for all medicines, data on the use of Rebif are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Rebif stalno spremljajo.
Some effect on progression of disability could be seen, but only in the patients who had relapses in the two years before the start of the study. 
Opaziti je mogoče določen učinek na napredovanje invalidnosti, vendar le pri bolnikih, ki so imeli zagone v dveh letih pred začetkom študije.
What benefits of Rebif have been shown in studies? 
Kakšne koristi zdravila Rebif so se pokazale v študijah?
Side effects reported with Rebif are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Rebif, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
What are the risks associated with Rebif? 
Kakšna tveganja so povezana z zdravilom Rebif?
Why is Rebif authorised in the EU? 
Zakaj je bilo zdravilo Rebif odobreno v EU?
When first starting treatment with Rebif, the dose should be slowly increased from a starting dose of 8.8 micrograms three times a week to avoid side effects. 
Po prvi uvedbi zdravljenja z zdravilom Rebif je treba odmerek počasi povečati od začetnega odmerka 8,8 mikrograma trikrat na teden, da se preprečijo neželeni učinki.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rebif have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Rebif upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
An overview of Rebif and why it is authorised in the EU 
Pregled zdravila Rebif in zakaj je odobreno v EU
The probability of developing MS over 24 months was 62.5% for patients given Rebif three times a week and 75.5% for patients given Rebif once a week compared with 85.8% for patients given placebo. 
Verjetnost razvoja multiple skleroze v 24 mesecih je bila 62,5 % pri bolnikih, ki so prejemali zdravilo Rebif trikrat na teden, in 75,5 % pri bolnikih, ki so prejemali zdravilo Rebif enkrat na teden, v primerjavi s 85,8 % pri bolnikih, ki so prejemali placebo.
What is Rebif and what is it used for? 
Kaj je zdravilo Rebif in za kaj se uporablja?
For more information about using Rebif, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Rebif glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
The most common side effects with Rebif (which may affect more than 1 in 10 people) are flu-like symptoms, neutropenia, lymphopenia and leucopenia (low white blood cell counts), thrombocytopenia (low blood platelet counts), anaemia (low red blood cell counts), headache, inflammation and other reactions at the injection site, and increases in transaminases (liver enzymes). 
Najpogostejši neželeni učinki zdravila Rebif (ki se lahko pojavijo pri več kot 1 od 10 oseb) so gripi podobni simptomi, nevtropenija, limfopenija in levkopenija (nizko število belih krvnih celic), trombocitopenija (nizko število trombocitov v krvi), anemija (nizko število rdečih krvnih celic), glavobol, vnetje in druge reakcije na mestu injiciranja ter povečanja vrednosti transaminaz (jetrnih encimov).
A 22-microgram dose is recommended for patients who cannot tolerate the higher dose. 
Pri bolnikih, ki ne morejo prenašati višjega odmerka, je priporočen 22-mikrogramski odmerek.
Rebif (44 micrograms given once or three times a week) has also been compared with placebo in 515 patients who had experienced a single attack of demyelination. 
Zdravilo Rebif (44 mikrogramov, ki so ga dajali enkrat ali trikrat na teden) so primerjali tudi s placebom pri 515 bolnikih, ki so imeli samo en napad demielinizacije.
The doctor may advise the patient to take a fever-reducing painkiller before each injection and for 24 hours after injection to reduce the influenza (flu)-like symptoms that may occur as a side effect of treatment. 
Zdravnik lahko svetuje bolniku, naj pred vsakim injiciranjem in v 24 urah po injiciranju vzame protibolečinsko zdravilo za zniževanje povišane telesne temperature, da se zmanjšajo gripi podobni simptomi, ki bi se lahko pojavili kot neželeni učinek zdravljenja.
Rebif must not be used in patients who have severe depression or have thoughts of suicide. 
Zdravilo Rebif se ne sme uporabljati pri bolnikih s hudo depresijo in/ali samomorilnimi mislimi.
The recommended dose of Rebif is 44 micrograms given three times a week by injection under the skin. 
Priporočeni odmerek zdravila Rebif je 44 mikrogramov, ki se daje trikrat na teden z injiciranjem v podkožje.
The active substance in Rebif is the protein interferon beta-1a, one of a group of interferons that can be naturally produced by the body to help it fight against viruses and other attacks. 
Učinkovina v zdravilu Rebif je beljakovina interferon beta-1a, ki je ena od skupin interferonov, ki jih lahko telo naravno ustvari v boju proti virusom in drugim napadom.
Rebif is available as a solution for injection in prefilled syringes, prefilled pens and cartridges for use in an electronic injection device. 
Zdravilo Rebif je na voljo kot raztopina za injiciranje v napolnjenih injekcijskih brizgah, napolnjenih injekcijskih peresnikih ali vložkih za uporabo z elektronskim pripomočkom za injiciranje.
Rebif can also be used in patients who have had a single attack of demyelination accompanied by inflammation. 
Zdravilo Rebif se lahko uporablja tudi pri bolnikih, ki so imeli samo en napad demielinizacije, ki ga je spremljalo vnetje.
Rebif is a medicine used to treat patients with relapsing multiple sclerosis (MS). 
Rebif je zdravilo, ki se uporablja za zdravljenje bolnikov z multiplo sklerozo (MS) z zagoni.
The exact way that Rebif works in MS is not yet known but the active substance, interferon beta-1a, seems to calm down the immune system, and prevents relapses of MS. 
Natančen način delovanja zdravila Rebif pri multipli sklerozi še ni znan, vendar se zdi, da učinkovina, interferon beta-1a, pomirja imunski sistem in preprečuje zagone multiple skleroze.
For the full list of side effects and restrictions with Rebif, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Rebif glejte navodilo za uporabo.
Patients received either Rebif (22 or 44 micrograms) or placebo (a dummy treatment) for two years. 
Bolniki so dve leti prejemali bodisi zdravilo Rebif (v odmerku 22 ali 44 mikrogramov) ali placebo (zdravilo brez učinkovine).
Rebif was more effective than placebo in reducing the number of relapses in relapsing MS. Relapses were reduced by about 30% over two years for both Rebif 22 and 44 micrograms compared with placebo, and by 22% (Rebif 22 micrograms) and 29% (Rebif 44 micrograms) over four years. 
Število zagonov se je v dveh letih zmanjšalo za približno 30 % ob jemanju zdravila Rebif v odmerkih 22 in 44 mikrogramov v primerjavi s placebom, in za 22 % (z zdravilom Rebif v odmerku 22 mikrogramov) in za 29 % (z zdravilom Rebif v odmerku 44 mikrogramov) v štirih letih.
Rebif's effectiveness has not been shown in patients with secondary progressive MS (the type of MS that comes after relapsing MS) that is not relapsing. 
Učinkovitost zdravila Rebif ni bila dokazana pri bolnikih s sekundarno progresivno multiplo sklerozo (vrsto multiple skleroze, ki sledi tisti z zagoni), ki nimajo zagonov.
How is Rebif used? 
Kako se zdravilo Rebif uporablja?
The patients can inject Rebif themselves once they have been trained. 
Bolniki si lahko po ustreznem usposabljanju zdravilo Rebif injicirajo sami.
Rebif contains the active substance interferon beta-1a. 
Zdravilo Rebif vsebuje učinkovino interferon beta-1a.
Rebif can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of MS. 
Predpisovanje in izdaja zdravila Rebif je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravljenjem multiple skleroze.
Rebif has been studied in 560 patients with relapsing MS. 
Zdravilo Rebif so raziskovali pri 560 bolnikih z multiplo sklerozo z zagoni.
How does Rebif work? 
Kako zdravilo Rebif deluje?
It is used when the patient is considered to be at high risk of developing MS. Before using Rebif, doctors need to exclude other causes for the symptoms. 
Pred uporabo zdravila Rebif morajo zdravniki izključiti druge možne vzroke za simptome.
Relapsing MS is the type of MS where the patient has attacks (relapses) between periods with no symptoms. 
Multipla skleroza z zagoni je vrsta multiple skleroze, pri kateri ima bolnik napade (zagone) med obdobji brez simptomov.
Rebif has also been studied in patients with secondary progressive MS. Rebif had no significant effect on the progression of disability, but the relapse rate was reduced by about 30%. 
Zdravilo ni bistveno vplivalo na napredovanje invalidnosti, stopnja zagonov pa se je znižala za približno 30 %.
3 x 30 tablets (multipack) 
3 x 30 tablet (pakiranje po več enot)
In addition, the Committee was of the opinion that more information was needed about how the medicine is absorbed, modified and removed from the body. 
Poleg tega je bil odbor mnenja, da je potrebnih več informacij o absorpciji in modifikaciji zdravila ter njegovem odstranjevanju iz telesa.
The main measure of effectiveness was improvement in vision. 
Glavno merilo učinkovitosti je bilo izboljšanje vida.
Progressive means that symptoms get steadily worse over time. 
Progresivna oblika pomeni, da se simptomi sčasoma vztrajno slabšajo.
Symptoms include weakness, difficulty walking and problems with vision. 
Simptomi vključujejo oslabelost, težave s hojo in vidom.
Qizenday is a medicine that contains the active substance biotin. 
Qizenday je zdravilo, ki vsebuje zdravilno učinkovino biotin.
Three of these enzymes are involved in energy production, while a fourth is believed to be involved in the production of sheaths around the nerve cells. 
Trije od teh encimov so vključeni v proizvodnjo energije, četrti pa naj bi bil vključen v tvorbo ovojnic okrog živčnih celic.
Withdrawal of the marketing authorisation application for Qizenday (biotin) EMA/821654/2017 
Umik vloge za pridobitev dovoljenja za promet z zdravilom Qizenday (biotin) EMA/821654/2017
The second study involved 93 patients with multiple sclerosis who had visual loss due to inflammation of the optic nerve. 
V drugo študijo je bilo vključenih 93 bolnikov z multiplo sklerozo, pri katerih je prišlo do izgube vida zaradi vnetja vidnega živca.
The mechanism of action of Qizenday in multiple sclerosis is not well understood; however, it is thought that the medicine acts on enzymes (known as carboxylases) to increase energy production in the damaged nerves and to help repair the protective sheath around the nerve cells. 
Mehanizem delovanja zdravila Qizenday pri multipli sklerozi ni dobro znan; vendar pa se domneva, da zdravilo deluje na encime (znane kot karboksilaze), s čimer poveča proizvodnjo energije v poškodovanih živcih in pomaga popravljati zaščitno ovojnico okrog živčnih celic.